Want to see CNTN full AI Analyst Report?
CNTN Stock Chart & Stats
$3.27
-$0.07(-3.02%)
At close: 4:00 PM EST
$3.27
-$0.07(-3.02%)
Day’s Range― - ―
52-Week Range$1.08 - $9.08
Previous CloseN/A
VolumeN/A
Average Volume (3M)636.65K
Market Cap
$161.19M
Enterprise Value$637.67
Total Cash (Recent Filing)$41.53M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.85
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding77,122,580
10 Day Avg. Volume300,267
30 Day Avg. Volume636,647
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.24
Price to Sales (P/S)0.00
P/FCF Ratio-6.02
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance Sheet With Large Equity BaseA zero-debt balance sheet and sizable equity cushion materially reduce financial risk and interest burden over the medium term. This capital base gives management flexibility to fund strategic initiatives or absorb operating losses without immediate refinancing, supporting survival through product development cycles.
Authorized $50M Share Repurchase ProgramA large buyback authorization indicates management confidence in capital allocation and provides a structural tool to return capital and reduce share count. Over time, disciplined repurchases can enhance per-share metrics and signal prioritization of shareholder value alongside strategic pivots.
Strengthened Governance And Board ContinuityClear committee assignments and re-election of directors improve oversight and decision discipline, reducing governance execution risk. Consistent governance structures help with vetting related-party transactions and strategic pivots, increasing institutional investor confidence over the medium term.
Bears Say
Pre-revenue Business ModelA sustained pre-revenue profile leaves long-term value dependent on successful development or strategic asset monetization. Without proven commercial products, the business lacks internal revenue coverage for operating spend, making outcomes binary and reliant on external financing or successful asset sales.
Widening Losses And Persistent Cash BurnMaterially increasing net losses and recurring negative operating and free cash flow create ongoing funding needs. Over a 2–6 month horizon these trends threaten capital runway unless spending is cut or new resources are raised, and continued burn risks eroding the current equity cushion over time.
Divestiture Reduces Clinical R&D Exposure; Limited Immediate CashSelling the clinical-stage R&D arm removes an in-house development engine and shifts future upside to contingent milestones and an unsecured note. That transforms cash flow prospects from potential product revenue to credit/milestone risk, reducing direct organic upside and making outcomes more binary and partner-dependent.
Canton Strategic Holdings News
CNTN FAQ
What was Canton Strategic Holdings’s price range in the past 12 months?
Canton Strategic Holdings lowest stock price was $1.08 and its highest was $9.08 in the past 12 months.
What is Canton Strategic Holdings’s market cap?
Canton Strategic Holdings’s market cap is $161.19M.
When is Canton Strategic Holdings’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Canton Strategic Holdings’s earnings last quarter?
Currently, no data Available
Is Canton Strategic Holdings overvalued?
According to Wall Street analysts Canton Strategic Holdings’s price is currently Overvalued.
Does Canton Strategic Holdings pay dividends?
Canton Strategic Holdings does not currently pay dividends.
What is Canton Strategic Holdings’s EPS estimate?
Canton Strategic Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Canton Strategic Holdings have?
Canton Strategic Holdings has 77,122,580 shares outstanding.
What happened to Canton Strategic Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Canton Strategic Holdings?
Currently, no hedge funds are holding shares in CNTN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Canton Strategic Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Increased
By 443.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $343.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 7.7%
Last 30 Days ▼ 7.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.12%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9999.00%
Trailing 12-Months
Company Description
Canton Strategic Holdings
Canton Strategic Holdings Inc., which was formerly known as Tharimmune, Inc. until its name change in February 2026, focuses on two primary areas. The company is committed to promoting the institutional integration of blockchain technology and fostering the digitization of financial markets, primarily by leveraging Canton Coin and offering support to the Canton network. In addition to its blockchain initiatives, the company is also deeply involved in pharmaceutical research and development. Its pipeline includes GV104, a buccal film technology designed to address respiratory and/or nervous system depression in military personnel and chemical incident responders, which has already finished its Phase 1 trial. Another significant project is GV023, an oral version of infliximab, engineered to resolve the key inconvenience of the standard intravenous treatment by eliminating the need for recurring infusions. Established in 2017, Canton Strategic Holdings Inc. is headquartered in Red Bank, New Jersey.
Technical Analysis
CervoMed
―
―
Champions Oncology
―
Pelthos Therapeutics
―
Artiva Biotherapeutics, Inc.
―
Ownership Overview
1.21% Insiders
1.00% Mutual Funds
<0.01% Other Institutional Investors
90.67% Public Companies and
Individual Investors